EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diagnostic performance of biparametric versus multiparametric MRI for prostate cancer: a noninferiority, confirmatory observer study

Xingyu Fang, Jialin Li, Wei Lv, Lin Liu, Jing Feng, Li Liu, Feng Pan, Yijun Zhang

Frontiers in Oncology · 03.06.2026 · 16

DOI: 10.3389/fonc.2026.1808035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 03.06.2026. Verfasst von Xingyu Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, the 305 Hospital of PLA, Beijing, China. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aimed to assess the noninferiority of biparametric MRI (bpMRI) compared to multiparametric MRI (mpMRI) using Prostate Imaging Reporting and Data System (PI-RADS) in diagnosing prostate cancer (PCa). Additionally, we compared diagnostic performance of bpMRI and mpMRI between expert and non-expert readers.

Methods

A total of 319 men with abnormal serum prostate-specific antigen (PSA) were included in the study and underwent mpMRI examinations. Two expert readers and two non-expert readers sequentially assessed bpMRI and mpMRI using the PI-RADS scoring system, respectively. The noninferiority of bpMRI versus mpMRI was evaluated using the area under the receiver operating characteristic curve (AUROC) alongside the sensitivity and specificity at a threshold of PI-RADS 3. The diagnostic performance and inter-observer agreement of bpMRI and mpMRI were compared between expert and non-expert readers.

Results

The prevalence of clinically significant PCa (csPCa) was 55.5% (177/319), bpMRI showed noninferior diagnostic performance to mpMRI in AUROC (0.896 [95% CI, 0.879-0.943] vs 0.911 [95% CI, 0.861-0.931]; difference of -1.5% [95% CI, -3.1% to 0.1%], p < 0.001), alongside sensitivity (92.8 [95% CI, 90.1-95.6] vs 93.8 [95% CI, 91.2-96.6]; difference of -1.0% [95% CI, -2.0% to 0.0%], p < 0.001) and specificity (69.4 [95% CI, 63.6-73.9] vs 73.1[95% CI, 67.1-76.9]; difference of -3.5% [95% CI, -6.1% to -1.4%], p < 0.01) at a threshold of PI-RADS 3. In bpMRI interpretation, specificity showed significant differences among readers (P = 0.001); expert readers (32.7%, 209/638) and non-expert readers (37.0%, 236/638) showed significant differences in PI-RADS 3 (P = 0.01) and moderate agreement (0.64 [0.53-0.71]).

Conclusion

The diagnostic performance of bpMRI in detecting csPCa was noninferior to that of mpMRI in a selected high-risk cohort of men with abnormal serum PSA. Limited additional benefits of DCE were observed for non-expert readers. Specialized system training of PI-RADS for non-experts or diagnosis under the supervision of expert radiologists might be better alternatives.

Schlagwörter

Stichwörter der Autor:innen

PI-RADSbiparametric MRIdynamic contrast-enhanced imagingmultiparametric MRIprostate cancer

Autor:innen und Institutionen

  • Department of Radiology, the 305 Hospital of PLA, Beijing, China.
  • Department of Laboratory, The 305 Hospital of PLA, Beijing, China.

Zitieren

APA

Fang, X., Li, J., Lv, W., Liu, L., Feng, J., Liu, L., Pan, F., & Zhang, Y. (2026). Diagnostic performance of biparametric versus multiparametric MRI for prostate cancer: a noninferiority, confirmatory observer study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1808035

Vancouver

Fang X, Li J, Lv W, Liu L, Feng J, Liu L, et al. Diagnostic performance of biparametric versus multiparametric MRI for prostate cancer: a noninferiority, confirmatory observer study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1808035

BibTeX
@article{Fang2026,
  author = {Fang, Xingyu and Li, Jialin and Lv, Wei and Liu, Lin and Feng, Jing and Liu, Li and Pan, Feng and Zhang, Yijun},
  title = {Diagnostic performance of biparametric versus multiparametric MRI for prostate cancer: a noninferiority, confirmatory observer study},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1808035}
}
Kostenlos starten →